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adherence and ‘successful’ prescribing. Doctors and nurse 
prescribers assessed the appropriateness of medications they 
considered to be within their competency. Doctors provided 
support to nurse prescribers and general practitioners (GPs) 
when dealing with issues around prescribing. Conclusion 
Assessment of the appropriateness of prescribed medica-
tions is complex. The recent reduction in medical expertise 
in specialist addiction services may negatively impact on the 
clinical management of service users. It appears that there is 
a need for further training of nurse prescribers and GPs so 
they can provide optimal care to service users.
Keywords Appropriateness · Medications · Medical 
prescribers · Nurse prescribers · Specialist addiction 
service · United Kingdom
Impacts on practice
• Nurse prescribers and doctors in a specialist addiction 
service differ in the types of medications they review but 
appear to be working within their competency.
• Decreasing medical expertise in addictions may pose a 
threat to quality decision-making by nurse prescribers.
• The decreasing availability of medical expertise in addic-
tion services presents a challenge to the management of 
complex service users by GPs.
• There is a need to provide training and support to nurse 
prescribers and GPs on prescribing for people with sub-
stance misuse problems, so that they can provide optimal 
care to specialist addiction service users.
Abstract Background Mental and physical health prob-
lems are common in people with substance misuse prob-
lems and medications are often required in their manage-
ment. Given the extent of prescribing for service users who 
attend specialist addiction services, it is important to con-
sider how prescribers in this setting assess the appropriate-
ness of service users’ prescribed medications. Objective To 
explore prescribers’ views and experiences of assessing the 
appropriateness of medications prescribed for service users 
coming in for treatment as well as the differences between 
prescribers. Setting A specialist addiction service in the 
North of England. Method A phenomenological approach 
was adopted. Semi-structured interviews were conducted 
with four nurse prescribers and eight doctors. Data were 
analysed using thematic framework analysis. Main outcome 
measure Prescribers’ views and experiences of assessing the 
appropriateness of prescribed medications. Results Assess-
ment of the appropriateness of prescribed medications 
involved reviewing medications, assessing risk, history-tak-
ing, involvement of service users, and comparing guideline 
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Introduction
People with substance misuse problems often have co-exist-
ing physical and/or mental health conditions [1, 2], and are 
prescribed a large number of medications which may some-
times not be justified [3]. Service users who seek treatment 
in specialist addiction clinics are more likely to have higher 
levels of dependence and complex needs that include social 
problems, functional impairment, comorbidities and use of 
multiple medications when compared with those who do not 
seek help [4, 5]. These complex needs may influence pre-
scribing decisions made for this population [6]. For instance, 
prescribing may be targeted at maintaining equilibrium in 
the lives of service users, which may lead to prescribing 
outside of guideline recommendations. Furthermore, ser-
vice users may want certain medications such as opioids and 
benzodiazepines prescribed for non-medical reasons [7, 8].
Opioids used in pain treatment and benzodiazepines for 
mental health problems have been implicated in the occur-
rence of adverse events in people with substance misuse 
problems. Benzodiazepines, antidepressants, antipsychotics 
and substances such as alcohol have often been found to be 
used in combination with opioids such as dihydrocodeine 
and oxycodone in opioid-related overdose and fatalities 
[9–11]. Antidepressant prescriptions, especially tricyclic 
antidepressants (hereafter TCAs), have also been linked to 
heroin overdose [12, 13].
The large number of people entering specialist addiction 
services with complex needs and multiple prescriptions 
provides an important opportunity for exploring addiction 
service prescribers’ views and experiences of assessing the 
appropriateness of medications prescribed for service users 
coming in for treatment as well as the differences between 
the various types of prescribers. Prescribers included in 
this study were medical and non-medical. The non-medical 
prescribers (NMPs) were independent nurse prescribers 
who could assess and also devise a treatment plan that may 
include prescribing for service users [14]. NMPs prescribe 
within their areas of competence [15]. For instance, nurse 
prescribers working in addiction medicine are able to pre-
scribe substitute opioids, relapse prevention medications, 
medications for detoxification and vitamin supplements.
Assessment of the clinical appropriateness of non-medi-
cal prescribing, including nurse prescribing, have concluded 
that NMPs generally make clinically appropriate prescribing 
decisions [16, 17]. However, history taking, assessment and 
diagnosis skills have been highlighted as areas for further 
attention.
Service users visiting the service could self-refer or be 
referred from a range of sources such as general practition-
ers, psychiatrists, hospital, social services, drug services 
and the criminal justice system. Consequently, this study 
explored specialist addiction service prescribers’ views and 
experiences of assessing the appropriateness of medications 
prescribed by others.
Aim
This study explored specialist addiction service prescribers’ 
views and experiences of assessing the appropriateness of 
medications prescribed for service users coming in for treat-
ment as well as the differences between prescribers. Appro-
priateness was considered to involve maximising effective-
ness, minimising risks and costs, and respecting the patient’s 
choice [18].
Ethics approval
The study was approved by the University of York’s 
Research Governance Committee and the National Research 
Ethics Service (NRES) Committee Yorkshire & The Hum-
ber. Reference 12/YH/0325.
Methods
Study design and setting
A phenomenological approach was taken to explore individ-
ual views and experiences of assessing the appropriateness 
of medications prescribed for service users. Semi-structured 
qualitative interviews were carried out with prescribers com-
prising nurse prescribers and medical doctors working at the 
specialist addiction service. This service is located in a city 
in the North of England and is a statutory NHS specialist 
service that provides tier 3 level interventions to adults who 
misuse alcohol and/or drugs. Tier 3 interventions generally 
involve the provision of care-planned interventions follow-
ing a comprehensive community-based assessment [19]. 
One-on-one interviews were used because it would be very 
difficult to get time-pressed clinicians together for a focus 
group discussion. In addition, group interviews may be pro-
hibitive for some prescribers.
Participants
Twelve prescribers took part in this study, comprising four 
nurse prescribers and eight medical doctors. In line with 
qualitative research inquiry, the aim of the sampling strat-
egy adopted was to recruit respondents who could provide 
valuable insight into the topic and also to provide a broad 
overview of the perspectives of different prescribers. Conse-
quently, all the fourteen prescribers working at the specialist 
addiction service during the period of this study were pro-
vided with the study details by the chief investigator (A. O). 
This was followed by a meeting with each prescriber to 
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discuss the study in detail after which written informed con-
sent was sought. Twelve of the fourteen eligible prescribers 
were interviewed. Participants included five females, three 
of whom were nurse prescribers and two medical doctors 
and seven males, of whom one was a nurse prescriber and 
six medical doctors. The medical doctors had different levels 
of seniority and included one senior house officer (hereafter 
SHO), one locum doctor, three specialist registrars (hereafter 
SpR) and three consultant addiction psychiatrists. Generally, 
the prescribers represented a broad range of qualifications 
and experience in the addiction field.1 Nurse prescribers’ 
ages ranged from 34 to 55 years while doctors were between 
31 and 65 years.
Data collection
Data were collected by the first author, A. O. All the inter-
views were conducted at a time convenient for participants 
at the specialist addiction service and lasted on average 
48 min (range 36–74 min). The topic guide was informed 
by knowledge of the literature on prescribing and advice 
from the project advisory group (which included one con-
sultant addiction psychiatrist). The topic guide was piloted 
with a consultant addiction psychiatrist and covered the fol-
lowing areas: definition of inappropriate prescribing, classes 
of medications assessed and how assessment is carried out. 
The interviews were audio recorded (with permission) and 
transcribed verbatim.
Data analysis
Data were analysed using thematic framework analysis [20]. 
Familiarisation involved repeated reading of transcripts 
alongside listening to the audio-recordings and was followed 
by a period of descriptive and interpretive coding facilitated 
by Atlas ti (v 6.0). This inductive approach enabled a deeper 
understanding of the data [21]. As new themes emerged, 
they were added to the coding framework. Broader themes 
were subsequently generated and frequently reviewed 
while comparing data from participants that supported the 
themes and also looking for explanations of any differences 
of viewpoints within the data. Numbers rather than names 
were allocated to participants in order to ensure anonymity 
and confidentiality. Trustworthiness of the data was ensured 
through an audit trail kept by A.O which detailed how data 
were collected, how themes were formed and how decisions 
were made during the research process. Furthermore, the 
interpretation of the data was discussed in-depth with two 
of the authors (C.L and E.H), who reflected on the plausibil-
ity of the themes and the depth of the analysis. A. O has a 
pharmacy background while C. L and E.H have criminology 
and nursing backgrounds respectively. D.R is a consultant 
addiction psychiatrist.
Results
The following themes emerged in response to how prescrib-
ers assessed the appropriateness of prescribed medications: 
review of medications, assessing risk, guideline adherence 
versus successful prescribing, history-taking and involve-
ment of service users. There were some areas of differences 
in nurse prescribers and medical doctors’ approaches and 
also among the different types of medical doctors. These 
differences are highlighted in the text.
Review of medications
The classes of medications reviewed varied among prescrib-
ers with three of them (all doctors) with the longest years 
of prescribing experience stating that they reviewed all of 
service users’ medications for their appropriateness. One of 
these three prescribers had 41 years of experience in pre-
scribing and made the following statement:
So I’d look at the list of drugs prescribed and see how 
they matched up to what I thought the person was 
showing in terms of addiction illness, physical illness 
and mental illness [P3, consultant].
The remaining prescribers consisting of other doctors and 
nurse prescribers described a more limited remit. These doc-
tors considered their scope of practice to encompass medica-
tions for mental health illnesses, addictions and sometimes 
opioids for pain relief while nurse prescribers described a 
focus on medications used for treating addiction problems. 
This quote captures a nurse prescriber’s view:
So I don’t really see, with psychiatric medication, that 
that would be within my remit really. If somebody 
came and they were prescribed 100 mgs of metha-
done and they couldn’t even open their eyes then, I 
would be assessing the appropriateness of the dosage 
and making necessary adjustments to things like that 
[P10, NP].
Nurse prescribers further described involving doctors at 
the specialist addiction service or service users’ general 
practitioners (hereafter GPs) if they had particular con-
cerns about medications. There was an underlying feeling 
1 Nurse prescribers had practiced in addiction specialty for between 
1 and 5 years and as nurses for between 5 and 22 years. Two doctors 
had no prior experience in addiction specialty while the remaining 
had between 6  months and 35  years of experience. Consultant psy-
chiatrists in particular, had between 3 and 35 years of experience in 
addiction specialty. Doctors had between 6 and 41  years of clinical 
experience.
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of cautiousness characterised by their perceptions of their 
competency. This was captured by the quote below:
As I say, if I was particularly concerned about some-
one’s mood or I have particular concerns about the 
medication I would defer to a medic. You know, it’s 
not an area I feel strongly confident on [P6, NP].
Doctors at the specialist addiction service were a valu-
able source of support to nurse prescribers in prescribing-
related issues. There was also particular reliance on the 
expertise of consultant addiction psychiatrists by both 
nurse prescribers and doctors who were not consultants. 
A doctor described contacting a GP concerning an inap-
propriate medication and the support of her consultant in 
providing expert advice when needed:
For the example I started with [patient with schizo-
phrenia on supra-BNF dose of olanzapine], I wrote 
to the GP saying, you know, Mr So-and-So is stable 
and is relatively symptom free on this but I’m wor-
ried about this monitoring [olanzapine monitoring] 
but generally if I think something’s really inappro-
priate and I’m in a position to contact the original 
prescriber I’ll try to do that, but I’d always discuss a 
case with my consultant and make a decision about 
whether or not I need to do something imminently 
[P12, SHO].
It appears that prescribers at this specialist addiction ser-
vice provided a ‘safety net’ function to other prescribers 
such as GPs:
If I find something that’s maybe been overlooked 
or prescribed wrongly, then I will let the GP know 
about it [P5, Locum].
I’d probably look at it [medication appropriateness] 
at the initial assessment and if there’s anything that 
comes up or that was sort of glaringly obvious I’d 
refer to the GP and ask the GP to review, if they’re 
prescribing [P11, NP].
Specialist addiction service prescribers further described 
GPs’ varying responses to the need for review of service 
users’ medications:
Yeah. that has happened on a couple of times where 
I’ve written to the GP to ask them to review… there 
have been a couple of scenarios where I’ve written 
and the GP hasn’t responded or the GP has written 
back saying, I don’t feel I’m the best person to do 
this, would you refer to a specialist service or would 
you basically will you deal with it [P12, SHO].
They also described sometimes taking over prescribing of 
psychiatric medications from GPs:
But in general I’d like to take over all of the psychoac-
tive drugs that somebody gets, at least until the point 
that we’re sure that the drugs are appropriate and we’ve 
got some sort of stable situation [P3, Consultant].
Assessing risk
The evaluation of risk is a theme that was highlighted by 
all prescribers as a means through which they assess the 
appropriateness of service users’ medications. All the twelve 
prescribers said they considered the risk posed by a medica-
tion. Some of the quotations captured this:
Well if it’s going to do, first of all, less harm than the 
actual substance, not more harm, so the actual pre-
scription can be worse than doing nothing [P5, locum 
doctor].
One prescriber described a service user who she felt had an 
inappropriate and high risk prescription of olanzapine (an 
antipsychotic). The service user was an elderly man who was 
being prescribed olanzapine (25 mg) at a dose higher than 
that stated in the British National Formulary (BNF) without 
monitoring by a psychiatrist:
I have a patient who has a very old diagnosis of para-
noid schizophrenia dating from his late teens, and for 
this he’s prescribed a very high dose of medication 
called olanzapine and he’s prescribed over the limit 
in the BNF and he’s not under the supervision of a 
specialist. So I would label that as an inappropriate 
prescription because (a) he’s elderly, which means that 
he’s more prone to cardiac disease, and the drug can 
cause diabetes which can lead to heart disease. It can 
cause arrhythmias, he’s not being monitored regularly 
with regards to that, and he’s not being monitored with 
regards to his clinical symptoms, which, are actually, 
from a psychosis point of view, negligible [P12, SHO].
The SHO described contacting the service user’s GP con-
cerning the antipsychotic medication. His GP refused to 
alter it due to the service user’s stability on the dose for a 
prolonged period. The GP and SHO differed in their views 
concerning the antipsychotic. There was no change made to 
the antipsychotic.
Guideline adherence versus successful prescription
The need to assess if prescribing is in line with guidelines 
was highlighted. Some prescribers further acknowledged 
that the need to individualise prescribing and ensure opti-
mal functioning may lead to prescribing outside guideline 
recommendations. The need to consider the context of pre-
scribing was emphasised by a nurse prescriber:
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And I think any comment about any prescribing should 
only be made when you know about the circumstances 
in which the decision was made. For example, we pre-
scribe very high doses of some drugs, now some peo-
ple say that you shouldn’t prescribe at those levels, but 
they are appropriate if you know about the circum-
stances [P1, NP].
A consultant addiction psychiatrist also expressed similar 
views and contrasted guideline adherence with successful 
prescribing:
Prescribing is something of an art as well as a science, 
so prescribers will sometimes prescribe things that 
they know are not really indicated but with the aim of 
achieving a particular goal [P3, Consultant].
History‑taking
All prescribers identified history-taking as a part of their 
assessment of the appropriateness of service users’ medi-
cations. The prescribers described enquiring about service 
users’ medical and medication history:
Looking at the history of their substance use, history 
of any physical health problems, mental health history, 
and current mental state as well so I’d get the full his-
tory and I think then you can kind of gauge whether 
something might be inappropriately prescribed [P11, 
NP].
 Despite prescribers routinely obtaining a medical/medica-
tion history from service users, most reiterated that it was 
not within their remit to explore the appropriateness of all 
prescribed medications:
…I would, in as much as part of the assessment, I 
would ask the service user …are they on any medi-
cations. If they are, what it is, what dose, what’s it 
prescribed for and are they taking it. That would be 
the total sum of my assessment. I wouldn’t move to 
beyond exploring that condition or whether that was 
appropriate, I don’t think that’s my place [P6, NP].
All prescribers further described some challenges with self-
report when obtaining service users’ histories. These include 
problems with the reliability of information provided by 
service users as some of them may withhold information. 
This may lead to prescribing of unnecessary medications. 
Prescribers also described service users who do not know 
details of their medications such as the name and reason 
for medication use. Some may be cognitively impaired by 
substances and therefore unable to provide necessary infor-
mation. Prescribers may have to contact GPs concerning 
needed information. There was however an acknowledg-
ment that contacting GPs for information was not always 
routine practice as prescribers tended to rely on information 
obtained from service users.
Involvement of service users
This theme was described by all prescribers. It involved 
discussing with service users in order to understand their 
views concerning the appropriateness of their prescribed 
medications:
Well, firstly I discuss with the patient to see what the 
patient’s view is, and explain what I think, which are 
the reasons for this inappropriateness [P13, SpR].
Prescribers also highlighted the fact that lack of engage-
ment by service users may affect prescribing decisions. For 
instance, service users’ medications may need to be stopped 
due to repeated non-attendance of clinic appointments.
Discussion
The evidence from this study shows that the assessment of 
the appropriateness of prescribed medications is a complex 
judgment. Besides a few more experienced doctors, all other 
prescribers (doctors and nurse prescribers) tended to review 
only the subset of medications which they saw as within 
their competency. It has been recommended that doctors 
and nurse prescribers adhere to their areas of competency 
for safe practice [22, 23]. Nurse prescribers and doctors 
appeared to be working within their competency.
Published evidence suggests non-medical prescribers 
generally make clinically appropriate prescribing decisions 
with the need for further improvement in assessment, diag-
nosis and history-taking skills [16, 17]. Nurse prescribers 
described referring service users who they had concerns 
about their medications to doctors at the specialist addiction 
service or service users’ GPs. Specialist addiction service 
doctors particularly represented a valuable source of sup-
port to nurse prescribers when dealing with issues around 
prescribing. The more junior doctors (non-consultants) also 
relied on their senior colleagues, especially consultant addic-
tion psychiatrists, for expert advice on medications. There 
was further evidence that prescribers were a sort of ‘safety 
net’ against medication-related risks as they intervened and 
contacted GPs if they found serious problems with service 
users’ medications.
Service users pose particular challenges in terms of 
complexity and risk issues. They often have complex needs 
including severe comorbid mental and physical health prob-
lems [24–29]. In order to meet these needs, Public Health 
England [23] has recommended that addiction specialist 
doctors such as consultant psychiatrists work alongside non-
medical prescribers and other doctors in a multidisciplinary 
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team. The drug and alcohol treatment system has however 
undergone some changes in commissioning in recent years. 
This has involved a move from mainly NHS service provi-
sion to a more mixed economy of service providers [23]. 
These changes have led to a decrease in the number of doc-
tors including consultant addiction psychiatrists in treatment 
systems [23], with nurses taking on more prescribing roles. 
Consequently, there is a reduction in the capacity of these 
new treatment systems for specialist expertise and complex 
case management.
It appears that there is a possibility of reduction in the 
quality of prescribing and decision-making as a result of 
these changes as nurse prescribers and GPs may not have 
ready access to support and specialist knowledge when 
required. The potential for specialists to provide clinical 
supervision that will support nurse prescribers in making 
clinically appropriate decisions when needed is also ham-
pered. It appears future prescribing practice in alcohol and 
drug treatment systems will mostly involve nurse prescrib-
ers. This raises concerns about the future review practices 
of psychiatric medications in addiction services if nurse 
prescribers are not further strengthened to work with ser-
vice users, including complex clients. In addiction service 
users, psychiatric comorbidity is highly prevalent [25–28] 
and medications used in their management have often been 
implicated in overdose and fatalities [11–13]. Pharmacists’ 
support could be enlisted to guide prescribing decisions for 
service users with complex comorbidity. This approach may 
assist in improving medicines management among service 
users.
There is the need to equip nurse prescribers to work with 
service users, especially complex cases. Given that assess-
ment, diagnosis and history-taking skills are pre-requisites 
for undertaking the nurse prescribing qualification, these 
skills may well be further developed through training to 
enable nurse prescribers manage complex service users, 
especially those with comorbid mental disorders. Practice 
should include regular supervision of nurse prescribers by 
an experienced doctor or nurse prescriber to ensure that they 
are making optimal clinical decisions.
The relationship between healthcare professionals and 
service users have changed over the years from a predomi-
nantly paternalistic model to one in which service users have 
increasingly become active partners whose views are impor-
tant [30, 31]. Involving service users assists the prescriber in 
eliciting their views and is useful in decision-making con-
cerning treatment [32]. There is evidence that building a 
positive relationship can lead to positive client and treatment 
outcomes [33]. Despite these potential benefits, prescribers 
identified problems that may occur when trying to involve 
service users in decision-making. The quality of informa-
tion provided by service users may be poor as a result of 
cognitive impairment or even deliberate withholding of 
information. When service users are actively misusing sub-
stances, prescribers lose access to the most fundamental tool 
in medicine, the patient’s self-report [34]. While some pre-
scribers described contacting service users’ GPs for further 
information concerning medications, this was not done by 
all prescribers.
Depending on information obtained from only service 
users in assessing appropriateness implies that medications 
which are potentially inappropriate may not be identified 
if service users fail to mention them. There is the possi-
bility that different prescribers may go ahead to prescribe 
undisclosed medications such as multiple central nervous 
system depressants. In addiction medicine, there should be 
careful consideration of self-report and collateral informa-
tion should be sought where possible [34]. Shared medical 
records [35] and good communication among different ser-
vice providers are essential in obtaining accurate medical/
medication histories and reducing the potential for multiple 
prescribing, drug interactions, overdose incidents and con-
flicting treatment plans [34].
The limited applicability of guidelines to service users 
was also recognised by prescribers. Guidelines often have a 
disease-specific focus and limited applicability to the vary-
ing needs of individual patients [36]. Although prescribing 
outside guideline recommendations carries its own risks 
including the potential for greater severity of unwanted 
side effects [37], there needs to be a weighing of such risks 
against more pragmatic outcomes that may be of great 
importance to service users.
Strengths and limitations
To the knowledge of the authors, this is the first study to 
explore the views and experiences of specialist addiction 
service prescribers when assessing the appropriateness of 
prescribed medications among service users coming to this 
setting. Owing to the fact that the interviews were conducted 
with prescribers after they had taken part in an earlier study 
in which the appropriateness of opioids and psychiatric med-
ications were assessed using a modified form of the Medica-
tion Appropriateness Index [38], it is possible that participa-
tion in this initial study may have influenced some of their 
responses to the different areas explored in the interviews. 
Consequently, prescribers’ responses might be different if 
they were interviewed before taking part in this initial study.
The findings may lack generalisability to prescribers in 
other addiction services, especially given the changes that 
have occurred in drug and alcohol treatment services in the 
UK. There has been an increase in the number of third sector 
organisations (non-statutory service providers and the pri-
vate sector) providing drug and alcohol services. Availability 
of medical expertise has also diminished in these services. 
Further research should involve multiple sites (including 
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services run by the NHS and third sector organisations), to 
establish if the findings of this study are applicable. Given 
the reducing levels of medical expertise among staff in spe-
cialist addiction services, an important area to explore will 
be the role and scope of nurse prescribers: including their 
views on the changing drug treatment landscape, manage-
ment of service users (especially those with complex needs), 
the support available to nurse prescribers and their training 
needs. Similarly, there may well be need to interview GPs 
on these areas since it was evident that specialist addiction 
service prescribers provided some level of support to them.
Furthermore, data collection was by a single researcher. 
There is the possibility that the researcher’s own perspec-
tives may have affected interpretations that were made. How-
ever, the conduct, analysis and interpretation of data were 
overseen by two of the authors in addition to A.O.
Conclusion
Assessment of the appropriateness of prescribed medica-
tions appeared to be a complex judgment. Optimal assess-
ment of prescribing appropriateness should involve a balance 
between guideline recommendations, risks and benefits of 
prescribing, and the context. Nurse prescribers and medical 
doctors differed in their approach to reviewing medications 
but appeared to be working within their competency, with 
doctors providing support to nurse prescribers when needed. 
Prescribers were a sort of ‘safety net’ against medication-
related risks to GPs. Recent changes in the UK drug and 
alcohol field have led to diminishing availability of medical 
expertise and an increasing reliance on non-medical pre-
scribing. These changes have the potential to affect the qual-
ity of decision-making around medications. It appears there 
is a need to further empower non-medical prescribers and 
GPs to effectively manage service users with comorbidity.
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